Marcie A. Goldstein
Lawyers
Filters
Jamf Holding $352 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the $352 million follow-on offering of 11,000,000 shares of common stock of Jamf Holding Corp. sold by…
Olema Pharmaceuticals $240 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public offering of 12,650,000 shares of common stock of Olema Oncology at $19…
Population Health Investment $172.5 million IPO
Davis Polk advised the sole book-running manager in connection with the $172.5 million initial public offering of 17,250,000 units of Population Health Investment Co., Inc., which includes…
Natural Order Acquisition $230 million IPO
Davis Polk advised the underwriters in connection with the $230 million initial public offering of 23,000,000 units of Natural Order Acquisition Corp., which includes 3,000,000 units…
Atea Pharmaceuticals $345 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…
Allegro MicroSystems $402.5 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $402.5 million initial public offering of 28,750,000 shares of common stock by Allegro MicroSystems,…
Biodesix $72 million IPO
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…
Bluescape Opportunities Acquisition $575 million IPO
Davis Polk advised the joint book runners in connection with the initial public offering of 57,500,000 units of Bluescape Opportunities Acquisition Corp. for aggregate proceeds of $575…
MediaAlpha $175.8 million IPO
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $175.8 million initial public offering of 10,637,500 shares of Class A…
Turning Point Therapeutics $460 million stock offering
Davis Polk advised the joint book-running managers in connection with a $460 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…